NeOnc wins UAE IND authorization for NEO100 in recurrent high-grade glioma

NeOnc Technologies Holdings, Inc.

NeOnc Technologies Holdings, Inc.

NTHI

0.00
  • NeOnc Technologies secured a second UAE Investigational New Drug authorization for NEO100, its intranasal therapy candidate for recurrent high-grade gliomas.
  • The Department of Health – Abu Dhabi clearance covers three clinical protocols spanning Phase 1 to Phase 2 adult studies, with a pediatric pathway included.
  • Topline results from the fully enrolled NEO100-01 Phase 2a trial are expected by end-July.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606240845PRIMZONEFULLFEED9751700) on June 24, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.